Drug Profile
IMR 261
Alternative Names: 10-nitro-oleic-acid; CXA-10; IMR-261Latest Information Update: 27 Feb 2023
Price :
$50
*
At a glance
- Originator Complexa
- Developer Complexa; Enliven Therapeutics
- Class Antihypertensives; Nitro compounds; Oleic acids; Small molecules; Unsaturated fatty acids; Urologics
- Mechanism of Action Heat-shock protein stimulants; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Toll-like receptor 4 antagonists; Xanthine dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Focal segmental glomerulosclerosis; Pulmonary arterial hypertension
- Preclinical Beta-thalassaemia; Sickle cell anaemia
- No development reported Acute kidney injury; Renal failure
Most Recent Events
- 23 Feb 2023 Imara Inc has been merged with Enliven Therapeutics to form Enliven Therapeutics
- 09 Jun 2022 Preclinical pharmacodynamics data presented at the 27th Congress of the European Haematology Association (EHA-2022)
- 14 Dec 2021 Imara plans clinical trial for Beta-thalassaemia and Sickle cell anaemia in 2022